ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$50.71M

FY 2025 · Annual

Investing Cash Flow

-$979,742.00

FY 2025 · Annual

Financing Cash Flow

-$1.76M

FY 2025 · Annual

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(60.8M)(64.2M)(27.74M)(27.76M)(40.52M)
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
Deferred Income Tax117K96K(78K)(197K)0
Stock-Based Compensation6.22M2.87M3.11M2.54M0
Change in Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Other Non-Cash Items1.11M(4.8M)(5.21M)(474K)3.94M
Operating Cash Flow(26.01M)(68.51M)21.55M(36.39M)(50.71M)
Capital Expenditures(484K)(708K)(1.37M)(1.42M)(979.75K)
Acquisitions (Net)00000
Purchases of Investments000(17M)0
Sales of Investments00017M0
Other Investing Activities59K6K5.65M(2.66M)0
Investing Cash Flow(425K)(702K)4.28M(4.07M)(979.74K)
Debt Repayment26.84M(45.05M)(2.63M)(1.58M)(1.91M)
Common Stock Issued108.48M14.12M071.64M66.28K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M34K354K223K75.19K
Financing Cash Flow136.83M(30.89M)(2.28M)70.28M(1.76M)
Effect of Forex Changes1.29M7.35M599K673K14.15M
Net Change in Cash111.69M(92.75M)24.15M30.48M(39.3M)
Free Cash Flow(26.5M)(69.22M)20.18M(37.81M)(51.69M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$40.5M
+ D&A$2.6M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$16.7M
+ Other Non-Cash$3.9M
= Operating Cash Flow-$50.7M
- Capex-$979.7K
= Free Cash Flow-$51.7M

Analysis

FY2025 free cash flow is -$51.7M. FCF conversion is 127.6% of net income. Operating cash flow was -$50.7M, with capex of -$979.7K. The largest bridge item is Working Capital at -$16.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 12, 2026
6-K6-K filingNov 12, 2026
6-K/A6-K/A filingOct 30, 2026
6-K6-K filingOct 28, 2026
6-K6-K filingSep 23, 2026

Does PRQR generate free cash flow?

ProQR Therapeutics N.V. (PRQR) generated -$51.69M of free cash flow in fiscal 2025.

How much operating cash flow does PRQR produce?

Operating cash flow was -$50.71M, before capital expenditures of $979,745.00.